Biovie company info

What does Biovie do?
Biovie (NASDAQ:BIVI) focuses on developing innovative treatments for serious medical conditions with unmet needs, primarily focusing on liver disease and certain rare conditions. The company is engaged in various stages of drug development, aiming to bring new therapeutic solutions to market. With a commitment to improving patient outcomes and quality of life, Biovie's projects range from pre-clinical trials to nearing commercial launch. The company's objectives include advancing their pipeline products through clinical development efficiently, securing partnerships to enhance capabilities, and achieving regulatory milestones to bring their innovations to patients in need. By concentrating on areas with significant therapeutic gaps, Biovie strives to make a meaningful impact in the medical field.
Biovie company media
Company Snapshot

Is Biovie a public or private company?

key
Ownership
Public

How many people does Biovie employ?

people
Employees
18

What sector is Biovie in?

pie chart
Sector
Health Care

Where is the head office for Biovie?

location pin
Head Office
Carson City, United States

What year was Biovie founded?

founded flag
Year Founded
2013
What does Biovie specialise in?
/Chronic Liver Disease /Therapeutics Development /Phase 2 Trials /Advanced Cirrhosis Treatment /Neurological Disorders /BIV201 Therapy

What are the products and/or services of Biovie?

Overview of Biovie offerings
Developing therapies for Liver Cirrhosis caused by nonalcoholic steatohepatitis (NASH) through BIV201, which regulates blood pressure and ascites.
Exploring treatments to address Ascites, a common complication in liver cirrhosis patients, aiming at improving patient quality of life.
Pursuing research and development in drug discovery and formulation for chronic liver diseases, focusing on non-invasive, effective treatments.
Exploring innovations in biotechnology to address unmet medical needs in liver disease and related conditions.
Developing patient-centric solutions that enhance the therapeutic outcomes for individuals suffering from chronic liver ailments.

Who is in the executive team of Biovie?

Biovie leadership team
  • Mr. Cuong Viet  Do M.B.A.
    Mr. Cuong Viet Do M.B.A.
    President, CEO & Director
  • Ms. Joanne Wendy Kim CPA
    Ms. Joanne Wendy Kim CPA
    CFO, Treasurer & Corporate Secretary
  • Dr. Joseph M. Palumbo M.D.
    Dr. Joseph M. Palumbo M.D.
    Executive VP of R&D and Chief Medical Officer
  • Mr. Clarence N. Ahlem
    Mr. Clarence N. Ahlem
    Senior Vice President of Operations
  • Dr. Penelope  Markham Ph.D.
    Dr. Penelope Markham Ph.D.
    Senior Vice President of Liver Disease Program
  • Ms. Denise  Smith
    Ms. Denise Smith
    Senior Vice President of Manufacturing & Development
  • Dr. Christopher L. Reading Ph.D.
    Dr. Christopher L. Reading Ph.D.
    Senior Vice President of Alzheimer's Disease Program
  • Ms. Sarah Overton Hoit
    Ms. Sarah Overton Hoit
    Chief Social Impact Officer